

Funding Opportunities August 2025

2025 Funding Calendar

	July	Aug	Sept	Oct	Nov	Dec
Cancer Research Institute						
CRI Irvington postdoctoral fellowship						
Immuno-Informatics Postdoctoral Fellowship Program						
Irish Cancer Society						
Cancer Nurse Researcher Award 2025						
Health Research Board						
US Ireland Research and Development Partnership Programme						
Investigator led clinical trials programme 2025 (Formerly DIFA)						
Investigator-Led Projects (ILP) 2026						
Horizon Europe						
Cancer Mission calls						
Rising Tide						
Clinical Cancer Research Grants						
Research Ireland						
Investigators Programme						
Global Talent Ireland						
Frontiers for the Future – Awards						
SFI ERC Support Programme						
Strategic Partnership Programme						
SFI Discover Programme – Opportunistic Funding Mechanism						
SFI Research Centres – Spokes						
US-Ireland R&D Partnership Programme						
EPSRC-SFI Joint Funding of Research						

Enterprise Ireland						
Innovation Partnership Programme						
Commercialisation Fund						
EI Commercial case feasibility grant						
ERC Grants						
ERC Starting						
ERC Consolidator						
ERC Advanced						
ERC Synergy						
Horizon Europe						
Boosting the translation of biotech research into innovative health therapies						
Facilitating the conduct of multinational clinical studies of orphan devices and/or of highly innovative ("breakthrough") devices						
Wellcome Trust						
Career Development Awards						
Discovery Awards						
COST Actions						
	July	Aug	Sept	Oct	Nov	Dec

Cancer and Health-Related Funding Calls

Cancer Research Institute

Scheme	Eligibility	Amount	Remit	Deadlines
CRI Irvington postdoctoral fellowship	Open to those up to 5 years post-PhD, working in areas directly related to immunology or cancer immunology. An eligible project must fall into the broad field of immunology with relevance to solving the cancer problem	\$243,000 to cover a three-year fellowship	CRI seeks hypothesis-driven, mechanistic studies in both immunology and tumour immunology. The applicant and sponsor should make every effort to demonstrate the potential of the proposed studies to directly impact our understanding of the immune system's role in cancer	Deadlines on 1 March and 1 September annually.
Immuno-Informatics Postdoctoral Fellowship Program	Open to those up to 5 years post-PhD, working in areas directly related to immunology or cancer immunology. An eligible project must fall into the broad field of immunology with relevance to solving the cancer problem	\$243,000 to cover a three-year fellowship	CRI aims to support qualified scientists at academic research institutions who wish to receive dual training in immunology and data science. The fellowships will support both computational biologists who seek to strengthen their knowledge of immunology and cancer immunologists who seek training in computational biology, data science, and/or genomics	Deadlines on 1 March and 1 September

Irish Cancer Society

Scheme	Eligibility	Amount	Remit	Deadlines
2025 Cancer Nurse Researcher Award	This award is open to clinical-academic research partnerships in the Republic of Ireland. At a minimum, the team must have one nursing professional working in an oncology/cancer-related clinical role (Clinical Nurse Research Lead) and one researcher working in an academic role (Academic Research Lead).	up to €150,000 for a project of >18 months	Funding is intended to support a nurse-led, partnership-based research project between nursing professionals and academic researchers based in the Republic of Ireland. This award is a transformative investment in a nurse researcher who demonstrates great potential in driving and leading clinically relevant and innovative cancer research in Ireland	18 th September 2025

Horizon Europe Cancer Mission – Upcoming calls

Scheme	Eligibility	Amount	Remit	Deadlines
HORIZON-MISS-2025-02-CANCER-01: Sustained collaboration of national and regional cancer funders to support the Cancer Mission through translational research	All eligible entities	5 million	<p>The successful proposal should aim to deliver results that are directed and tailored towards and contribute to all the following expected outcomes:</p> <p>National and regional cancer funders across Europe (i.e. representing Northern, Southern, Central, Eastern and Western Europe), based on a common strategic research and innovation agenda, deliver:</p> <ol style="list-style-type: none"> 1. At least four transnational calls for proposals addressing translational cancer research, resulting in collaborative grants to academic investigator-led third parties; 2. Streamlined national, regional and foundation-based or charity-based practices in organising peer-reviewed translational cancer research and innovation funding between the partners, with attention to exploring novel funding schemes and initiatives as well as sustainability of a network of funders where appropriate 	16 th September 2025

HORIZON-MISS-2025-02-CANCER-02: Understanding the effects of environmental exposure on the risk of paediatric, adolescent and young adults cancers	All eligible entities	Approx 6-7 million per project	<p>Project results are expected to contribute to some of the following expected outcomes:</p> <p>Researchers and health professionals will advance our understanding on how environmental, genetic and epigenetic, omics and other factors interact in determining the onset and development of cancers in children, adolescents and young adults and how they impact health outcomes in young cancer patients.</p> <p>Policymakers and public health authorities have scientific evidence to improve prevention strategies to minimise the impacts of environmental factors on the development and progression of paediatric, adolescent and young adult cancers.</p> <p>Researchers, innovators, and professionals from across different disciplines and sectors will support and contribute to the future UNCAN.eu research data platform by ensuring interoperability of data, new digital tools and models.</p>	16 th September 2025
HORIZON-MISS-2025-02-CANCER-03: Innovative surgery as the cornerstone	All eligible entities	Approx 7-10 million per project	Proposals under this topic should aim to deliver results that are directed and tailored towards, and	16 th September 2025

<p><u>of affordable multi-modal therapeutic interventions benefitting cancer patients with locally advanced or metastatic disease</u></p>			<p>to contribute to all of the following expected outcomes:</p> <p>Patients have access to tailored, affordable, effective and—when appropriate—minimally-invasive surgery-centred, multi-modal treatment interventions targeting locally advanced or metastatic disease;</p> <p>Researchers, innovators[1], SMEs and other professionals from different disciplines and sectors have access to innovative surgery-centred treatment technology and medical devices for further improvements and validation;</p> <p>National healthcare providers, policymakers and authorities in European regions, Member States and Associated Countries have the evidence to implement affordable surgery-centred treatment solutions that benefit cancer patients with locally advanced or metastatic disease in their healthcare systems;</p>	
---	--	--	---	--

HORIZON-MISS-2025-02-CANCER-04: Investigator-initiated multinational early-stage innovative clinical trials for paediatric cancer	All eligible entities	Approx 3-5 million per project	Expected Outcomes: Children and adolescents with cancer have access to innovative, more effective, less toxic treatments—both in terms of acute toxicity and long-term late effects—and care solutions; National healthcare providers, policymakers and authorities in European regions, Member States and Associated Countries have the scientific evidence to accelerate the implementation of affordable and accessible treatment and care solutions in their healthcare systems; Researchers, innovators, and professionals from different disciplines and sectors ensure accessibility and re-usability of relevant trial data, to support the future UNCAN.eu research data platform, which is currently in preparation.	16 th September 2025
HORIZON-MISS-2025-02-CANCER-05: Pragmatic clinical trials to enhance the quality of life of older cancer patients (65 years and older) through nutrition	All eligible entities	Approx 3-5 million per project	Expected Outcomes: Older cancer patients have access to and benefit from tailored nutritional care-oriented interventions as part of routine treatment or care interventions, which improves treatment outcomes,	16 th September 2025

			<p>alleviates disease symptoms and side effects and enhances their survival and quality of life;</p> <p>National healthcare providers, policymakers and authorities in European regions, Member States and Associated Countries have the evidence to implement tailored nutritional care as part of routine cancer treatment or care interventions in their healthcare systems, including in everyday medical practice.</p>	
HORIZON-MISS-2025-02-CANCER-06: Support to the network of National Cancer Mission Hubs (NCMHs)	All eligible entities	11 million	<p>This topic will ensure the continuation of the work of supporting the creation of a Network of National Cancer Mission Hubs (NCMHs) in Member States and Associated Countries. NCMHs in each Member State and Associate Country are to operate for the whole duration of the Cancer Mission and beyond. It was envisaged that there would be a second phase of support to build on the achievements and needs identified under the ECHoS project[1] during the first phase.</p>	16 th September 2025

			<p>Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes:</p> <ul style="list-style-type: none"> • The Network and NCMHs are supported to ensure the integration of Cancer Mission activities at national, regional, and local levels; • Stakeholders, including patients and citizens, in national, regional or local health and research and innovation systems engage in policy dialogues on cancer; • Citizens, including patients, are involved in citizen engagement activities, including their design and development, which will lead to recommendations being made to governments, helping to implement and adapt strategies to national and regional needs; 	
--	--	--	--	--

			<ul style="list-style-type: none"> Regional and national policy makers and authorities benefit from activities carried out in the implementation of Cancer Mission actions. 	
--	--	--	--	--

Health Research Board¹

Scheme	Eligibility	Amount	Remit	Deadlines
Investigator led clinical trials programme 2025 (Formerly DIFA)	Aimed at mid-stage or senior stage researchers. It is strongly recommended that the Lead Applicant should have experience in the conduct of interventions.	Definitive Intervention studies - €1,300,000 (including overheads) for up to 60 months. Feasibility Studies – €430,000 (inclusive of overheads) for 12 – 36 months.	This call supports research that addresses questions of direct relevance to the improvement of patient care, health of the public and health services and that has strong potential to have immediate use for decision makers in everyday clinical practice or policy. €3M (25%) of the total ILCT Programme budget is aimed at supporting cancer-specific trials (both definitive intervention and or	12/12/2025

¹ If you don't hold a PhD degree, you may need to demonstrate PhD equivalency (based on research experience post primary degree). This must be granted by HRB prior to submission of an application.

			feasibility studies) quality permitting within the overall call.	
US Ireland Research and Development Partnership Programme	Open to mid-career and senior researchers. Must have at least one applicant from each jurisdiction (USA, Republic of Ireland, and Northern Ireland) and must all contribute significant research participating		Goal is to increase the level of collaborative R&D amongst researchers and industry in all 3 jurisdictions	Open – Rolling Deadline
Investigator-Led Projects (ILP) 2026	Applications should be made on behalf of a team made up of researchers, knowledge user(s) and PPI contributors. The Lead Applicant must: Hold a post (permanent or a contract that covers the duration of the award) in a HRB recognised Host Institution (the “Host Institution”) as an independent investigator. For clinicians, an adjunct position in a	Maximum total €430,000 over 24 - 48 months	This call aims to support highly innovative and internationally competitive investigator-led projects that can respond to existing and emerging challenges for health and social care. The objectives are to: Fund research that addresses important questions for health and social care Support high quality, internationally relevant research	14 th October 2025

	<p>HRB recognised Host Institution is acceptable. OR</p> <p>Be an individual who will be recognised by the Host Institution upon receipt of an award as an independent investigator who will have a dedicated office and research space for the duration of award, for which they will be fully responsible. The Lead Applicant does not necessarily need to be employed by the Host Institution at the time of the application submission.</p> <p>Show evidence of achievement as an independent researcher in their chosen research field.</p> <p>Only one application per Lead Applicant to this scheme will be considered</p>		<p>Add to the knowledge base at an international level</p> <p>Support research that will lead to an improved visibility and standing for Ireland</p>	
--	---	--	--	--

<p>HRCI-HRB Joint Funding Scheme 2026</p>	<p>This call is open to HRB recognised Host Institutions in Ireland and other non-ROI Host Institutions.</p> <p>Funding outside Ireland is allowable where there is no established research capacity in Ireland (e.g. for the case of rare diseases).</p> <p>Applications should be made as a team made up of researchers, knowledge user(s) and PPI contributors.</p> <p>Applicants must have a suitable track record and demonstrate clearly that the research team contains the necessary breadth and depth of expertise in all methodological areas required for the development and delivery of the proposed project.</p> <p>Lead Applicants must:</p> <p>Hold a post (permanent or a contract that covers the duration of the</p>	<p>€30k over 12-36 months</p>	<p>This call enables HRCI-registered research charities to support research of particular interest to specific patient populations. The scheme provides funding for research projects in disease areas that are of strategic relevance to individual HRCI-registered research charities.</p>	<p>Opening 1 September 2025</p>
---	---	-------------------------------	--	-------------------------------------

	award) in a HRB recognised Host Institution as an independent investigator. For clinicians, an adjunct position in a HRB recognised Host Institution is acceptable. OR Be an individual who will be recognised by the Host Institution upon receipt of an award as an independent investigator who will have a dedicated office and research space for the duration of award. The Lead Applicant does not necessarily need to be employed by the Host Institution at the time of the application submission.			
<u>Upcoming – Research in-Practice Fellowships for Health and Social Care Practitioners (RFP) 2026 (prev Clinician Scientist Fellowships)</u>	Hold a PhD degree or defend their PhD thesis before 1 September 2026 or be able to demonstrate equivalent research experience as defined in the 'Towards a European Framework for Research Careers'.	80K over 4-5 years	The scheme is designed to support health and social care practitioners who wish to advance their research skills at post-PhD level while continuing to deliver patient or social care. It targets health and social care	Expected to open 1 October 2025

	<p>Have completed their professional training</p> <p>Hold (or will hold at the time of the award being made):</p> <p>a clinical post in the Irish health service or social care organisation which covers or will cover the duration of the award if successful (e.g., SpR, hospital consultant, nurse practitioner, public health practitioner, physiotherapist), or</p> <p>a clinical post in a private practice, or</p> <p>a post in a health and social care organisation, or</p> <p>a joint clinical and academic teaching/education position without a research element within a Higher Education Institution and the Irish Health Services or other social care organisations, or</p>		<p>practitioners from a variety of professional backgrounds, who are interested in advancing applied health and social care research aimed at finding practical solutions to specific problems</p>	
--	--	--	--	--

	<p>if not currently working in Ireland, have the support of a HRB approved HI and have already obtained or are negotiating a post in a clinical or a social care services organisation in the Republic of Ireland.</p>			
--	--	--	--	--

IHI

Scheme	Eligibility	Amount	Remit	Deadlines
IHI Call 11	Applicant consortia must ensure that at least 45% of the action's eligible costs are provided by contributions from industry members, their constituent or affiliated entities, and contributing partners.	€12 Million for all projects	<p>The following topics are under consideration for inclusion in IHI call 11, a two-stage call.</p> <ul style="list-style-type: none"> • Towards precision medicine: platform for transdiagnostic stratification of brain dysfunction • Understanding how infections foster and induce non-communicable diseases • AI-powered signal detection in pharmacovigilance • Leveraging Europe's expertise to accelerate cell therapy for type 1 diabetes • Establishing ortho and cardiology ambulatory surgical centres in Europe 	TBC

Rising Tide Foundation

Scheme	Eligibility	Amount	Remit	Deadlines
Clinical Trials Cancer Research Grants	Applicants must hold a doctoral degree and have a faculty appointment (or equivalent) with an academic institution. Both early-career and established investigators are encouraged to apply	RTFCCR does not cover the full clinical trial cost. RTFCCR normally funds USD 100,000 per each year of the trial duration, up to 5 years.	This grant supports innovative and unique patient-centred clinical trials with the potential to impact the lives of cancer patients. The aim is to improve cancer patients' treatment options and quality of life by funding clinical studies focused on therapy optimization, disease and treatment burden, and early detection and intervention. Rising Tide fund phase I to phase III interventional clinical trials.	24 th November

Irish Funding Schemes – General

Research Ireland

Scheme	Eligibility	Amount	Remit	Deadlines
Global Talent Ireland	<p>The programme is only open to Rising Stars and Research Leaders who are currently employed <u>outside</u> of Ireland</p> <p>Rising Stars:</p> <p>Have obtained a PhD qualification (or equivalent) within 5-15 years of the current year</p> <ul style="list-style-type: none"> • Have an outstanding track record commensurate with their career stage and their field(s) of research • Have secured independent research funding from competitive 	<p>Rising Stars: 2.25M</p> <p>Research Leaders: 3.25M</p>	<p>This Global Talent Ireland call will consider proposals that demonstrate excellence in any research area that falls within Research Ireland's remit, where Applicants can provide compelling evidence for their potential to contribute to national development.</p>	<p>EOI Deadline: 28th August 2025</p>

	<p>publicly funded sources as a Lead Investigator or Co-Investigator</p> <ul style="list-style-type: none"> • Have experience of supervising MSc- and/or PhD-level students • Have demonstrated international standing as an indicator of research maturity <p>Research Leaders:</p> <p>Have obtained a PhD qualification (or equivalent) at least 16 years prior to the current year</p> <ul style="list-style-type: none"> • Hold a full professorial position at a major international research institution or an equivalent senior research-active role in an industrial setting • Demonstrate influential research 			
Research Ireland Investigators Programme	The Lead Applicant and any Co-Applicant must be a member of <u>academic</u> staff in an Eligible Research Body, and hold either a	Up to €625,000	This call supports all disciplines across the full spectrum of endeavour—from curiosity-driven research that generates new knowledge, to applied research	Internal Deadline via Sesame: Wednesday 03 Sept 2025

	permanent contract or a contract that covers the period of the grant -		that seeks to develop solutions and innovations, including in the social and cultural domains.	Final Deadline to submit complete applications to RDO via Sesame: Wednesday 10 Sept EOI Deadline: 17 th September 2025
Frontiers for the Future – Awards	>3years post PhD. Other requirements	500k-1Million direct costs 4-5 years	Larger scale funding for innovative, collaborative and excellent research programmes that have the potential to deliver economic and societal impact.	Open - Rolling deadline
SFI ERC Support Programme		Maximum award of €300,000, which is provided as an overhead to the Host Institution of a recruited ERC awardee	Applications are invited from senior representatives of the Host Institutions of recruited awardees that have been funded through the ERC Starting Grant, Consolidator Grant, Advanced Grant or Synergy Grant schemes. The ERC awardee associated with the application must have succeeded in obtaining their award from a Host Institution outside of Ireland.	Open – Rolling Deadline

Strategic Partnership Programme	>3years post PhD. Other requirements	Amount requested must be matched and must be a minimum of €400k	Research must be aligned to SFI's legal remit: 1.The research should be oriented basic or applied; and 2.The research should align with one of the 6 Refreshed Priority Themes for 2018-2023 or with any other area where there is convincing evidence that there will be a significant potential for economic and/or societal impact in Ireland	Open – Rolling Deadline
SFI Discover Programme – Opportunistic Funding Mechanism	Call is open to a wide range of people and organisations		Aims to support and develop science, technology, engineering, and maths (STEM) education and public sector engagement in Ireland	Open – Rolling Deadline
SFI Research Centres – Spokes	Research needs to be oriented basic or applied, and should align with one of the 6 Refreshed Priority Themes for 2018-2023	Will provide a maximum of 50% of funding of the direct project costs	Is a vehicle to enable the addition of new industrial and academic partners and projects to existing SFI Research Centres.	Open – Rolling Deadline

US-Ireland R&D Partnership Programme	Must have at least one applicant from each jurisdiction (USA, Republic of Ireland, and Northern Ireland) and must all contribute significant research participating		Goal is to increase the level of collaborative R&D amongst researchers and industry in all 3 jurisdictions	Open – Rolling Deadline
EPSRC-SFI Joint Funding of Research	Find the eligibility criteria for EPSRC applicants here . The ROI SFI co-lead(s) must have a PhD or equivalent and be a member of academic staff of an eligible Research Body or a Contract Researcher.		Supports joint research and technology development in all areas of EPSRC remit which covers chemistry, engineering, information, and communication technologies, materials, mathematical sciences, and physics	Open – Rolling Deadline

Enterprise Ireland

Scheme	Eligibility	Amount	Remit	Deadlines
Innovation Partnership Programme	Company must be registered client of EI, IDA, local enterprise office.	Up to 80% of eligible costs up to 200k. Exceptions may be made. Express IPP application process for projects under €150k	To support collaborative research projects between Irish HEAs and companies. Co-funding from partner company required. Discuss with EI and TTO.	Outline proposal can be submitted any time. Full proposal deadlines: 1 st July, 5 th August, 2 nd September (generally a monthly deadline)
Commercialisation Fund	HEA researchers	Commercialisation Fund Award provides access to a range of funding and supports.	To convert outputs of state funded research into new products, services and companies. Funding is available to researchers to undertake research projects that address a gap or need in the market by developing innovations that can be commercialised in Ireland, will be licensable ideally within 2-5 years, can lead to the establishment of a start-up company.	Rolling – open call

EI Commercial case feasibility grant	HEA researchers	15k	<p>Perform Market analysis and validation</p> <p>Profile the competitor landscape</p> <p>Perform Patent landscaping and develop the IP strategy</p> <p>Investigate potential routes to exploitation to the economic benefit of Ireland</p> <p>Understand relevant regulatory issues or other barriers/hurdles to commercialisation</p> <p>Create a small demonstration or early prototype</p>	Rolling – to discuss with EI and TTO first
--	-----------------	-----	---	--

EU and International Funding Schemes - General

ERC Grants

Scheme	Eligibility	Amount	Remit	Deadlines
Starting	2-7 years post PhD	1.5M (plus 500k start-up costs, large equipment costs etc can be requested), 5 years	Designed to support excellent Principal Investigators at the career stage at which they are starting their own independent research team or programme. Applicant Principal Investigators must demonstrate the ground-breaking nature, ambition and feasibility of their scientific proposal	September/October annually – Expected October 2025
Consolidator	7-12 yrs post PhD	2 million (plus additional 1 million start-up costs), 5 years	Designed to support excellent Principal Investigators at the career stage at which they may still be consolidating their own independent research team or programme. Applicant Principal Investigators must demonstrate the ground-breaking nature, ambition and feasibility of their scientific proposal.	January/February annually
AdG	None, track record of significant research achievements in the last 10 years	2.5 million for a period of 5 years. An extra 1 million can be made	Designed to support excellent Principal Investigators at the career stage at which they are already established research	28 th August 2025

		available to cover start - up costs.	leaders with a recognised track record of research achievements. Applicant Principal Investigators must demonstrate the ground-breaking nature, ambition and feasibility of their scientific proposal.	
Synergy Grant	A group of 2 to maximum 4 Principal Investigators (PIs) working together and bringing different skills and resources to tackle ambitious research problems	10 million euro for a period of 6 years. An additional 4 million euro can be requested for start-up costs		Expected November 2025

Supports available:

- EI ERC proposal writing grant up to €16,000 – **now to be submitted to EI 6 months in advance of deadline**
- Pre-submission panel – project description and interview
- Expert workshops
- Expert review of draft proposal
- Assistance with budgets and ethics

Marie Skłodowska Curie Awards

Scheme	Eligibility	Amount	Remit	Deadlines
MSCA Doctoral Networks²	At least 3 independent entities in different EU MS or associated countries. Each beneficiary must recruit at least one doctoral candidate and can also organise secondments for them anywhere in the world.	<p>4 years, with each fellowship between 3-36 months. The EU provides support for each recruited researcher in the form of</p> <ul style="list-style-type: none"> a living allowance a mobility allowance if applicable, family, long-term leave and special needs allowances <p>In addition, funding is provided for</p> <ul style="list-style-type: none"> research, training and networking activities 	MSCA Doctoral Networks will implement doctoral programmes, by partnerships of universities, research institutions and research infrastructures, businesses including SMEs, and other socio-economic actors from different countries across Europe and beyond	25 November 2025

² **Industrial Doctorate:** doctoral candidates will step outside academia and develop skills in industry and business by being jointly supervised by academic and non-academic organisations, both of which can be established in the same EU Member State or Horizon Europe Associated Country.

Joint Doctorate: represent a highly integrated type of international, inter-sectoral and multi/interdisciplinary collaboration in doctoral training. They lead to the delivery of joint, double or multiple doctoral degrees⁹ recognised in at least one EU Member State or Horizon Europe Associated Country

		<ul style="list-style-type: none"> management and indirect costs 		
Postdoctoral Fellowships 2025	<p><u>European Postdoctoral Fellowships</u> are open to researchers of any nationality who wish to engage in R&I projects by either coming to Europe from any country in the world or moving within Europe. The standard duration of these fellowships must be between 12 and 24 months.</p> <p><u>Global Postdoctoral Fellowships</u> are open to European nationals or long-term residents^[1] who wish to engage in R&I projects with organisations outside EU Member States and Horizon Europe Associated Countries. These fellowships require an outgoing phase of minimum 12 and maximum 24 months in a non-associated Third Country, and a mandatory 12-month return phase to a host organisation based in an EU Member State or a Horizon Europe Associated Country.</p>		<p>Fellowships will be provided to excellent researchers undertaking international mobility. Applications will be made jointly by the researcher and a beneficiary in the academic or non-academic sector.</p>	10 th September 2025

--	--	--	--	--

Note: Attracting in MSCA postdoctoral fellows is an excellent way to build capacity in TSJCI

- For those involved in existing **ITNs, RISE or other collaborative networks**, we suggest starting a conversation with other hosts as to high potential ESRs who may wish to travel and apply for an IF with TCD.
- If you know of any senior postdocs currently abroad, it could be a good opportunity to encourage them to apply.

Horizon Europe – Framework Programme 9 [2021-2027]

Health Programme 2025 will launch shortly – selection of upcoming calls listed below

HORIZON-HLTH-2025-01-TOOL-05: Boosting the translation of biotech research into innovative health therapies	Further Information to follow	€6-8 Million	Proposals under this topic should aim to deliver results directed towards and contributing to most of the following expected outcomes: <ul style="list-style-type: none"> •Healthcare providers, researchers and patients get faster access to innovative therapies •Europe benefits from more clinical trials being conducted with new biotech therapeutic approaches •The competitiveness of European small and medium-size enterprises (SMEs) in the health biotech sector is strengthened 	18 th September 2025
HORIZON-HLTH-2025-01-IND-03: Facilitating the conduct of multinational clinical studies of orphan devices and/or of highly innovative (“breakthrough”) devices)	Further Information to follow	€4-5 Million	Proposals are expected to: <ul style="list-style-type: none"> •Increase Healthcare providers hands-on experience regarding the clinical use of orphan devices and of highly innovative (“breakthrough”) devices and get timely access to such devices with demonstrated clinical benefits; • collect and obtain scientific evidence on proposed intervention/ approach with the device under investigation; •Benefit patients from the development, studies and use of orphan devices and of highly innovative (“breakthrough”) devices 	18 th September 2025
HORIZON-HLTH-2025-01-TOOL-01 Enhancing cell		8-10 Million	This topic aims at the design of engineered cells to address the current limitations of cellular therapies, such as delivery efficiency, patient	

therapies with genomic techniques			<p>safety, in vivo persistence, desired therapeutic effect, immune tolerance and manufacturing workflows. The chosen approach should enable to control the characteristics, fate and function of the engineered cells from gene level onwards and thus lead to customised cells with improved therapeutic features.</p> <p>The use of genetic engineering and in particular gene editing tools should be a key element in the design of the engineered cells. The therapeutic action should be based on the endogenous capabilities of the cells; the exogenous loading of cells with drugs (using the cells as drug carrier) is not in scope.</p> <p>The engineered cells should be derived from human cells. Either stem cells or somatic cells may be used, but of allogeneic origin, thereby opening up the development of “off-the-shelf” cell therapeutic</p>	
-----------------------------------	--	--	---	--

Wellcome Trust

Scheme	Eligibility	Amount	Remit	Deadlines
--------	-------------	--------	-------	-----------

Career Development Awards	<p>Already driving your own research (you may have been appointed your first permanent contract within the last 3 years – can't ask for salary). If you are a health professional, you will have completed your clinical training. If you want to continue with clinical activities, you must be registered with, and licensed by, the relevant professional regulator in the country you intend to work in</p>	<p>Salary plus expenses; 8 years</p>	<p>Mid-career researcher and you are ready to lead a substantial and innovative research programme</p>	<p>20th November 2025</p>
Early Career Awards	<p>Open to early-career researchers (up to 3 years post-PhD) who are ready to design, plan and deliver your own innovative research project that aims to:</p> <ul style="list-style-type: none"> • advance understanding in your field <p>and/or</p> <ul style="list-style-type: none"> • develop methodologies, conceptual frameworks, tools 	<p>Salary plus up to £400,000 for research expenses, for up to 5 years</p>	<p>For early-career researchers from any discipline who are ready to develop their research identity. Through innovative projects, they will deliver shifts in understanding related to human life, health and wellbeing. By the end of the award, they will be ready to lead their own independent research programme.</p>	<p>30th September 2025</p>

	or techniques that could benefit health-related research.			
Discovery Awards	<p>Lead applicants must have International standing as a research leader in their field</p> <p>Experience of leading innovative and creative research</p> <p>Track record of managing and training others.</p> <p>Ability to commit 20% of time.</p>	Salary, equipment, and expenses for 8 years	<p>Aims to fund research questions that generate knowledge that leads to a shift in understanding or delivers new insight into how human life and health work. Proposals welcomed that may have a clinical or societal impact or have translational potential, but the focus should be on discovery research.</p> <p>Funded projects database</p>	25 th November 2025

COST ACTIONS

[COST Actions](#) are networks centred around nationally funded research projects in fields that are of interest to at least seven COST countries. The financial support averages EUR 130 000 per year for a four-year period.

For more information click here: www.cost.eu

Next deadline to submit new proposal – **21st October 2025**

[Congressionally Directed Medical Research Programs](#)

A number of opportunities in Breast Cancer, Lung Cancer, Ovarian Cancer and Prostate Cancer

Click here for more information: <https://cdmrp.health.mil/>

[EMBO Short-term fellowships](#)

Short-Term Fellowships fund research exchanges of **up to three months** between laboratories in eligible countries. The aim is to facilitate valuable collaborations with research groups applying techniques that are unavailable in the applicant's laboratory. The fellowships cover **travel plus subsistence** of the fellow only and not of dependents.

Applicants must be active researchers at any stage in their career with a minimum of one year of research experience at the PhD-student level. There is **no deadline for applications**, however it is recommended to apply three months before the proposed starting date.

Conference/Workshop Funding

Scheme	Eligibility	Amount	Remit	Deadlines
EMBO conference	Life science topic, any nationality	80-450 delegates, 2.5-5 days, 37k inc EMBO webpage and poster advertising		Twice a year, 1 March 2025, and 1 July 2025
Failte Ireland		Min 100 participants, 10 per person [international, includes NI].	Planning toolkit, Stock Ireland images/videos,	6 months in advance
Dublin Convention Bureau		Free Venue search, planning toolkit including maps, infographics, free pens		